Authored Content
Rare disease demands a unique playbook: The patient journey is rarely linear, the evidence base is often limited, and “rare” can have different meanings across settings and geographies. The third edition of our annual rare disease eBook explores the unique dynamics of the rare disease landscape and its implications for biotech stakeholders.
This third installment of our APAC rare disease series explores key enablers of achieving higher levels of multi-stakeholder collaboration in funding decisions for rare disease treatments.
Rare disease patient groups in APAC can amplify their impact through multi-stakeholder collaboration to achieve equitable access for people living with rare diseases.
Uncovering beliefs underpinning payer decision making can help global access teams achieve optimal and equitable patient access, faster.
As national reimbursement is no longer the only priority for global teams, value communication materials may evolve to enable meaningful, timely patient access.